Replies to post #327223 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

OUCH!

[BAR123]

On top of this being a huge issue for cassava it is potentially a bigger issue for the FDA who will then be investigated.

[frrol]

That's wild. The FDA just agreed to an SPA, then a couple hours later someone else in the agency files an (independent) petition to halt their trials.

They'd be looking all the way back to their IND and the biomarker research. At $4.7B MC the company's stock has a lonnng way to fall.

Let's see if the FDA acts on the petition. Might take a while.

[Bourbon_on_my_cornflakes]

WOW INCREDIBLY DIRTY TACTICS: Reason for Sava decline

So now the ambulance chasers are petitioning the govt to stop the trial? That is a new low even for the class action bar.

In a just world, these people would be afflicted with alz, along with their families.

Labaton Sucharow prosecutes precedent-setting class and direct actions, recovering billions of dollars on behalf of defrauded consumers and investors.

I had seen the petition. What is not understandable to me at least is why AVXL stock gets hit, too.

Simple. The market isn't buying Anavex 273 for alz yet. P2a data too old and trial too small. So we are linked to SAVA's credibility because we haven't produced credible p3 alz data of our own.

Quoting more myszy studies won't make any difference.

Of course, the problem could be fixed this fall if....

[tredenwater2]

Ouch! Looks like Billy Dunn MD is going to be a lot busier than he probably wants to be after the questionable Adehelm debacle. Looks like Dr. M’s strategy of using 3 party peer reviewed documents and letting the “data speaks for itself” is not a bad idea after all. With AI combing through all the data enriching the trial would only, imo, make it harder to “cook the books”, not easier.

The high road is not always the most profitable short term but he who laughs last laughs loudest!